Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,292 papers from all fields of science
Search
Sign In
Create Free Account
Neuroleptic Malignant Syndrome
Known as:
neuroleptic malignant
, malignant neuroleptic
, Neuroleptic Malignant Syndromes
Expand
A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
15 relations
2-Bromoergocryptine Mesylate
Adverse reaction to drug
Antipsychotic Agents
Bromocriptine
Expand
Broader (3)
Poisoning
Syndrome
nervous system disorder
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Neuropsychiatric Sequelae of Neuroleptic Malignant Syndrome
Adityanjee
,
M. Sajatovic
,
Kaizad R. Munshi
Clinical neuropharmacology
2005
Corpus ID: 25956906
The authors review the literature on persistent sequelae of neuroleptic malignant syndrome (NMS). They highlight the clinical…
Expand
Review
1994
Review
1994
Incidence and risk factors in neuroleptic malignant syndrome
H. Naganuma
,
I. Fujii
Acta Psychiatrica Scandinavica
1994
Corpus ID: 45142989
Between October 1981 and September 1989, 564 patients admitted to the Department of Psychiatry of the Hospital of Oita Medical…
Expand
Highly Cited
1991
Highly Cited
1991
Clozapine-induced neuroleptic malignant syndrome.
K. Dasgupta
,
A. Young
Journal of Clinical Psychiatry
1991
Corpus ID: 33659351
Neuroleptic malignant syndrome (NMS), a rare but serious side effect of psychotropic drugs, is usually attributed to blockade of…
Expand
Review
1991
Review
1991
Neuroleptic Malignant Syndrome or Parkinsonism Hyperpyrexia Syndrome
M. Granner
,
Wooten Gf
Seminars in neurology
1991
Corpus ID: 23170189
NMS is a rare and idiosyncratic reaction that occurs with the use of dopamine antagonists or the withdrawal of dopamine agonists…
Expand
Review
1987
Review
1987
The neuroleptic malignant syndrome.
S. Caroff
,
S. Mann
,
A. Lazarus
Journal of Clinical Psychiatry
1987
Corpus ID: 7515376
The neuroleptic malignant syndrome (NMS) is an evidently underdiagnosed but potentially lethal consequence of treatment with…
Expand
Highly Cited
1985
Highly Cited
1985
Syntheses and Specific Activity Determinations of No-Carrier-Added Fluorine-18-Labeled Neuroleptic Drugs
C. Shiue
,
J. Fowler
,
A. Wolf
,
Masazumi Watanabe
,
C. D. Arnett
1985
Corpus ID: 93917914
A generalmethodfor the synthesesof no-carrier-added(NCA)18F-labeled butyrophenone neuroleptics—benperidol, haloperidol…
Expand
Highly Cited
1983
Highly Cited
1983
Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action.
G. Reynolds
,
M. Rossor
,
L. Iversen
Journal of neural transmission. Supplementum
1983
Corpus ID: 32268368
It is well established that neuroleptic drugs are antagonists of brain dopamine receptors. The role of the reported increase in…
Expand
Highly Cited
1982
Highly Cited
1982
Modulation of long-term potentiation: Effects of adrenergic and neuroleptic drugs
T. Dunwiddie
,
N. Roberson
,
T. Worth
Pharmacology, Biochemistry and Behavior
1982
Corpus ID: 36999763
Highly Cited
1973
Highly Cited
1973
Influence of neuroleptic drugs and apomorphine on dopamine‐sensitive adenylate cyclase of retina
Joan Heller Brown
,
M. Makman
Journal of Neurochemistry
1973
Corpus ID: 39742417
THE NEUROLEPTIC drugs (major tranquilizers) selectively antagonize a number of behavioral and physiological actions of dopamine…
Expand
Highly Cited
1971
Highly Cited
1971
Importance of nervous impulse flow for the neuroleptic induced increase in amine turnover in central dopamine neurons.
N. Andén
,
H. Corrodi
,
K. Fuxe
,
U. Ungerstedt
European Journal of Pharmacology
1971
Corpus ID: 11887482
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE